News & Updates

Show Multimedia Only
Fluvoxamine wins, metformin disappoints in long COVID fatigue
Fluvoxamine wins, metformin disappoints in long COVID fatigue
19 Jun 2026 byElvira Manzano

The antidepressant fluvoxamine reduces long COVID fatigue, whereas the antidiabetic agent metformin fails to outperform placebo in the randomized REVIVE-TOGETHER trial.

Fluvoxamine wins, metformin disappoints in long COVID fatigue
19 Jun 2026
Reduced RT plus chemo-immunotherapy feasible in older/frail NSCLC patients
Reduced RT plus chemo-immunotherapy feasible in older/frail NSCLC patients
18 Jun 2026 byStephen Padilla

In older or frail patients with stage III non-small cell lung cancer (NSCLC), undergoing reduced radiotherapy (RT) followed by sequential chemo-immunotherapy results in survival outcomes similar to standard RT, indicating its utility in vulnerable populations, suggests a study.

Reduced RT plus chemo-immunotherapy feasible in older/frail NSCLC patients
18 Jun 2026
COVID-19 vaccine improves survival outcomes in cancer patients on ICI therapy
COVID-19 vaccine improves survival outcomes in cancer patients on ICI therapy
17 Jun 2026 byStephen Padilla

Vaccination against COVID-19 provides survival benefits to cancer patients receiving immune checkpoint inhibitors (ICIs), as shown in a recent study.

COVID-19 vaccine improves survival outcomes in cancer patients on ICI therapy
17 Jun 2026